Related Experiment Videos
Effect of isradipine on factors affecting blood viscosity
1Soroka Medical Center, Ben-Gurion University of the Negev, Beer Sheva, Israel.
Insights
Isradipine treatment improved red blood cell filtrability in hypertensive men. This calcium channel blocker enhanced blood flow by improving red blood cell deformability, offering potential benefits for hypertension management.
Area of Science:
- Cardiovascular Medicine
- Hematology
Background:
- Hypertension is associated with impaired red blood cell (RBC) deformability.
- Elevated fibrinogen, hematocrit, and mean corpuscular volume (MCV) are observed in hypertensive individuals compared to normotensive controls.
Purpose of the Study:
- To investigate the effect of isradipine on RBC filtrability in men with mild-to-moderate hypertension.
- To assess whether isradipine improves RBC deformability in hypertensive patients.
Main Methods:
- Prospective, double-blind, randomized study involving 20 hypertensive men and 9 normotensive controls.
- Patients received either isradipine or placebo. RBC filtrability and blood pressure were measured before and after treatment.
Main Results:
- Hypertensive patients exhibited higher fibrinogen, hematocrit, MCV, and impaired RBC deformability (filtration rate) compared to controls.
- Isradipine treatment significantly lowered blood pressure and improved RBC filterability (P < .05) compared to placebo.
Conclusions:
- Isradipine demonstrates a beneficial effect on RBC filterability in hypertensive men.
- The findings suggest that isradipine may improve RBC deformability, potentially contributing to its antihypertensive effects.
Abstract:
The objective of the study was to investigate the effect of isradipine on red blood cell filtrability in 20 men with mild-to-moderate hypertension. In this prospective, double-blind study, parallel groups of hypertensive male patients were randomized to receive either isradipine (n = 11) or placebo (n = 9). An additional group of nine normotensive age-matched volunteers served as controls. Tests were performed before and after patients were treated with either isradipine or placebo. The hypertensive patients differed from the normotensive controls in having a higher level of fibrinogen (P less than .04), a higher hematocrit (P less than .001), a higher filtration rate (P less than .05; impaired red blood cell deformability), and a higher mean corpuscular volume (MCV; P less than .005). Treatment with isradipine lowered blood pressure and improved red blood cell filterability (P less than .05) compared with placebo.